By Daniella Parra
Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) announced a strategic partnership with Quality Chemical Laboratories, Inc. to manufacture Comera’s lead SQore excipients.
Comera’s SQore platform transforms intravenously administered biologics into patient-delivered subcutaneous formulations, the company said in a statement.
“QCL is pleased to leverage its strong synthetic and analytical chemistry expertise to advance Comera’s technology platform,” said Dr. Yousry Sayed, President and CEO of QCL. “There has been a growing trend towards bringing back manufacturing of critical, high-value technologies such as pharmaceuticals to the United States to reduce supply risk, ensure high quality production and improve regulatory compliance.”